Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Oncolys Initiates Company-Sponsored PI Trial of Oncolytic Virus for Treatment of Esophageal Cancer
Oncolys BioPharma announced on July 7 that administration of the oncolytic virus Telomelysin has been initiated in the first patient in a company-sponsored PI clinical trial for the treatment of esophageal cancer.The PI trial will evaluate the safety and efficacy…
To read the full story
Related Article
BUSINESS
- Japan OTC Drug Market Falls for Third Straight Month in May: Intage
June 23, 2026
- Fycompa Generics Head for Summer Launch as Key Patent Expires
June 23, 2026
- Lilly Japan Names Karla Alcazar as New President
June 22, 2026
- Shionogi’s CEO Pay Up at 302 Million Yen in FY2025
June 22, 2026
- J-TEC Sets Up German Unit to Expand LabCyte Biz in Europe
June 22, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…